01—Abstract
Summary
Summary of the 8-K/A filed June 1, 2022. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K/A amendment on June 1, 2022, to provide updated details regarding the agreement with its Chief Financial Officer, David Meline.
The amendment clarifies that Mr. Meline will continue as CFO until December 31, 2022, or an earlier date when his successor begins. This transition includes a retirement date and an agreement for him to provide strategic consulting services to the company through March 2, 2026. The agreement outlines the compensation and equity vesting terms for Mr. Meline during and after his tenure as CFO.
This includes continued vesting of current equity awards and specific provisions for bonus awards and stock option exercisability post-employment. Investors should note the extended consulting period and the specific conditions tied to equity vesting and option exercise, as these impact the company's long-term engagement with a key executive.
02—Key points
Key Highlights
- David Meline will retire as Chief Financial Officer (CFO) on December 31, 2022, or when his successor starts.
- Mr. Meline will provide strategic consulting services to Moderna through March 2, 2026, following his retirement.
- His current base salary and benefits will continue until his Retirement Date.
- Equity awards (new hire equity, 2021 annual grant) will continue to vest through July 8, 2024.
- 2022 annual equity award will continue to vest through March 2, 2026.
- Mr. Meline will receive his 2022 annual bonus award at target, prorated for his employment period in 2022.
- Certain vested stock options will remain exercisable for twelve months after the Strategic Consulting Period ends, subject to original expiration dates.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K/A filing?
The primary purpose of this amended 8-K filing is to update the terms of the agreement with Chief Financial Officer David Meline, specifically detailing his retirement date and his subsequent role as a strategic consultant.
What are the key changes in Mr. Meline's employment agreement?
The key changes include establishing a firm retirement date for his CFO role (December 31, 2022, or sooner), outlining his transition to a strategic consulting role until March 2, 2026, and detailing the continuation of his equity vesting and bonus arrangements during and after his active employment.
How will Mr. Meline's compensation and equity be affected after his retirement as CFO?
After retiring as CFO, Mr. Meline will receive his 2022 annual bonus at target (prorated). He will also continue to vest in certain unvested equity awards through specific dates (July 8, 2024, and March 2, 2026) for providing consulting services, and some vested options will remain exercisable for a period after the consulting term.
What conditions are associated with Mr. Meline's post-retirement benefits?
Mr. Meline's post-retirement benefits, particularly related to equity vesting and option exercisability, are contingent upon his agreement to a general release and other standard terms and conditions, and his adherence to the consulting agreement, including not voluntarily resigning prior to the Retirement Date.
04—Continue